Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 27, 2025 20:55 ET | Source: InnoCare Pharma

InnoCare Announces First Patient Dosed in the Global Phase II Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Prurigo Nodularis

InnoCare's pipeline under development now covers ten major autoimmune diseases, with a particular focus on dermatological conditions.